AMW Further Strengthens Executive Leadership Team by Appointing Dr. Joerg Serafimov as Chief Business Officer

Warngau, Germany, January 9, 2024

AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that Dr. Joerg Serafimov has been appointed to the newly created role as Chief Business Officer (CBO), effective January 1, 2024. In this capacity, he is responsible for International Business and Licensing, Key Account Management, Business Development, Regulatory Affairs, Marketing and Public Relations at AMW.

“I am delighted to welcome Joerg to our leadership team, as AMW continues on its strategic growth path,” commented Philipp Karbach, CEO of AMW. “From a number of global leadership positions across the industry Joerg brings a wealth of experience to the Company and has a proven track record in scaling organizations and effectively driving commercial transformation processes. It is already a great pleasure working with Joerg, knowing that he will ideally complement our management team as we expand our production activities, while simultaneously increasing customer satisfaction. Joerg will play a key role in delivering on our commitment to being the partner of choice for our customers and business partners.”

“I am thrilled to join AMW in these decisive times and to become part of a passionate team of experts dedicated to improving the lives of patients with value-added medicines and innovative therapeutic solutions,” added Dr. Joerg Serafimov, CBO of AMW. “AMW has already taken impressive steps in its transformation process, and I am very excited to shape its commercial organization both globally and on a local level to enable further profitable growth by working closely with our present and future business partners.”

Dr. Serafimov is an experienced business leader with a track record of profitable growth in originator specialty drugs, generics and B2B business. With more than 15 years of professional experience in the pharmaceutical industry and management consulting, he combines a strong strategic business planning mindset with a profound commercial operations background. In global and local roles, he has gained extensive experience across the full product lifecycle, from multiple product launches to effective lifecycle management of mature brands. Dr. Serafimov joins AMW from Centrient Pharmaceuticals, The Hague, NL, a Bain Capital Portfolio Company, where he headed the Global Business Excellence team. He started his industry career in a consulting role at IMS Consulting (today IQVIA), before he moved to various global and local leadership positions at Novo Nordisk, Zurich and Mainz, and Sandoz International GmbH, Munich. Dr. Serafimov holds biochemistry and chemistry degrees from the universities of Heidelberg, Oxford, as well as from ETH Zurich.

###

About AMW:

AMW GmbH is a specialty pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.

AMW is based in Warngau near Munich, Germany.

For further information, please contact:

AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
Email: news@a-m-w.eu